Clinical Characteristics of T-Nonanaplastic Large-Cell Lymphoma and T-Anaplastic Large-Cell Lymphoma Patients
| Parameter . | Non-ALCL-T (n = 228) (%) . | ALCL-T (n = 60) (%) . | P Value . |
|---|---|---|---|
| Age ≤60 yr | 60 | 75 | .04 |
| Male | 68 | 73 | .4 |
| Female | 32 | 26 | |
| Stage | |||
| I-II | 14 | 30 | .001 |
| III-IV | 85 | 50 | |
| B-symptoms | 48 | 56 | .2 |
| PS >1 | 30 | 19 | .08 |
| ENS >1 | 40 | 23 | .01 |
| BM positive | 36 | 13 | .001 |
| Bulk >10 cm | 28 | 19 | .1 |
| Hepatomegaly | 23 | 15 | .1 |
| Splenomegaly | 39 | 13 | .001 |
| Skin lesions | 19 | 26 | .2 |
| LDH >NI | 55 | 34 | .004 |
| β2-microglobulin >NI | 55 | 32 | .01 |
| Hemoglobin <10 g/dL | 21 | 18 | .5 |
| Platelets <100 × 109/L | 7 | 11 | .3 |
| Eosinophils ≥0.8 × 109/L | 15 | 5 | .1 |
| Gammaglobulin >20 g/L | 10 | 0 | .001 |
| IPI score*: | |||
| 0 factors | 7 | 39 | .001 |
| 1 factor | 15 | 24 | |
| 2 factor | 26 | 14 | |
| ≥3 factors | 51 | 22 |
| Parameter . | Non-ALCL-T (n = 228) (%) . | ALCL-T (n = 60) (%) . | P Value . |
|---|---|---|---|
| Age ≤60 yr | 60 | 75 | .04 |
| Male | 68 | 73 | .4 |
| Female | 32 | 26 | |
| Stage | |||
| I-II | 14 | 30 | .001 |
| III-IV | 85 | 50 | |
| B-symptoms | 48 | 56 | .2 |
| PS >1 | 30 | 19 | .08 |
| ENS >1 | 40 | 23 | .01 |
| BM positive | 36 | 13 | .001 |
| Bulk >10 cm | 28 | 19 | .1 |
| Hepatomegaly | 23 | 15 | .1 |
| Splenomegaly | 39 | 13 | .001 |
| Skin lesions | 19 | 26 | .2 |
| LDH >NI | 55 | 34 | .004 |
| β2-microglobulin >NI | 55 | 32 | .01 |
| Hemoglobin <10 g/dL | 21 | 18 | .5 |
| Platelets <100 × 109/L | 7 | 11 | .3 |
| Eosinophils ≥0.8 × 109/L | 15 | 5 | .1 |
| Gammaglobulin >20 g/L | 10 | 0 | .001 |
| IPI score*: | |||
| 0 factors | 7 | 39 | .001 |
| 1 factor | 15 | 24 | |
| 2 factor | 26 | 14 | |
| ≥3 factors | 51 | 22 |
*Based on data from 261 PTCL and 1,433 BCL patients.